FOXO4-DRI 5 mg

POPULAR 2026 | RESEARCH LIBRARY

FOXO4-DRI

A plain-language research page on identity, mechanism, evidence, uncertainties and South African context.

Contents

Important information · Identity · Research questions · Mechanism · Evidence · Regulatory context · Comparison · Risks · Common questions · Research updates · Sources

Important information and disclaimer

This page is for education about published research. It does not advertise, offer or recommend FOXO4-DRI and does not provide dosing or self-treatment advice. Inclusion in an image concept pack is not evidence of a registered product, proven benefit or permission to market it.

An online label or certificate cannot alone establish identity, purity, sterility, strength, stability or suitability for human use. Anyone with serious symptoms should obtain clinical assessment rather than rely on an experimental peptide.

What is FOXO4-DRI?

FOXO4-DRI is an experimental cell-penetrating peptide designed to disrupt a FOXO4–p53 interaction in some senescent cells. It is a laboratory senolytic candidate, not an established anti-ageing medicine.

Identity distinctions that prevent confusion

FOXO4-DRI is not a general FOXO4 supplement, and evidence for other senolytics does not validate this particular peptide. A similar nickname, peptide family or visual label is insufficient to show chemical identity. Documentation must refer to the actual material and formulation under consideration.

What is FOXO4-DRI researched for?

The central hypothesis is that removing selected senescent cells could improve tissue function after stress or with ageing. Cell senescence also has useful roles, including in repair and tumour suppression, so selective targeting matters.

Other potential uses if future research confirms them

Research would need validated molecular identity, tissue targeting, dose selection, toxicity work and human trials before any disease claim. Kidney, fibrosis and endocrine hypotheses remain preclinical.

A future indication requires more than a plausible molecular pathway. Researchers need a defined patient group, an appropriate comparator, outcomes that matter to patients, and follow-up long enough to reveal important harms. The amount printed on a draft vial image answers none of those questions.

How might FOXO4-DRI work?

In the foundational study, the peptide displaced p53 from its interaction with FOXO4, triggering apoptosis preferentially in certain senescent cells. That mechanism cannot be assumed to operate safely in all human tissues.

Mechanistic work can identify a testable pathway, but it cannot specify a clinically useful route or prove that a laboratory signal will survive the complexity of a human disease. Exposure and target engagement should be measured in a study rather than inferred from a supplier label.

What has the evidence found?

The 2017 primary study reported cell and mouse results, including tissue outcomes after chemotherapy-related stress. Subsequent animal studies explore other disease models. No human efficacy or long-term safety trial establishes clinical benefit for FOXO4-DRI.

Evidence from cells, animals, hormone measurements or small clinical studies must be judged separately. A promising mechanism is a reason to investigate a question, not a demonstration of clinical efficacy.

How strong is the evidence?

The strongest evidence depends on the specific claim. A human pharmacology experiment may prove a short-term hormone response but not a health benefit; a small patient trial may identify an early signal but miss rare harms. Animal and cell findings are valuable for choosing the next experiment, while a well-designed clinical trial is needed for a treatment claim.

Current status and South African context

This page does not assert South African registration or a particular legal supply route. Before any public product listing, check the exact formulation, manufacturer and indication against current SAHPRA records and obtain professional regulatory review. SAHPRA warns about unregistered peptide products sold through informal channels.

How FOXO4-DRI compares with nearby concepts

FOXO4-DRI is not a general FOXO4 supplement, and evidence for other senolytics does not validate this particular peptide.

Risks and uncertainties

Eliminating cells in the wrong context could impair repair or have unforeseen effects. ‘Reverses ageing’ is a much larger claim than the measured animal outcomes.

Risk has at least two parts: the biological effects of the molecule, and the quality of a particular preparation. A published study using controlled material does not verify an unrelated online vial. For any injectable product, identity, sterility, endotoxin control and storage are distinct questions; a simple purity figure does not settle them.

Treatment and measurement safeguards

A clinician or investigator would first define the condition, baseline measurements and relevant standard treatment. Outcomes would be measured prospectively and adverse events recorded. The public research page should avoid conversion charts, injection instructions or promises about results, and should say when an established treatment is available.

Common questions

Is FOXO4-DRI a proven treatment?

Not for the broad claims often attached to its name. The evidence described here must be read for the exact indication, route and measured outcome.

Does a mechanism mean it works in people?

No. A receptor, cell or animal result supports a hypothesis; clinical benefit and safety require human testing.

Does the pictured strength validate a product?

No. The draft strength is an image identifier and must be checked against actual specifications before a listing.

Can two similar peptide names be substituted?

FOXO4-DRI is not a general FOXO4 supplement, and evidence for other senolytics does not validate this particular peptide.

Does a certificate or CAS number prove suitability for human use?

No. Such details may help identify a material, but they do not by themselves establish formulation, sterility, stability, authorisation or therapeutic value.

What would change this page?

A rigorous new trial, a corrected publication, a regulator decision or verified product specification could change a specific conclusion.

Join for research and regulatory updates

Readers who want to track FOXO4-DRI can set a periodic alert for its exact name plus ‘clinical trial’, ‘randomised’, ‘publication’ and ‘SAHPRA’. An AI reminder should bring back the study or regulator link, publication date, population, outcome and limitations. Verify the source before treating an alert as a change in evidence.

Sources and further reading

Foundational Cell study: https://pmc.ncbi.nlm.nih.gov/articles/PMC5556182/

Mouse Leydig-cell study: https://pmc.ncbi.nlm.nih.gov/articles/PMC7053614/

SAHPRA public peptide information: https://www.sahpra.org.za/peptide-products-public-information/

Research review date: 26 September 2026. Verify current trial and regulatory status before publication.